Project Grant HT94252410287

The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a Project Grant of $679,290 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for the period April 1, 2026 through March 31, 2031. The project focuses on translating novel hyperpolarized (HP) carbon-13 dual-agent magnetic resonance imaging (MRI) techniques to improve prostate cancer detection and biopsy guidance. The research aims to develop and...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Leland Stanford Junior University a Project Grant of $593,557 on March 18, 2026, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop magnetic resonance (MR) imaging methods for real-time measurement and control of BPM31510, an emerging lipophilic cancer therapy. The research addresses a critical clinical translation challenge by creating tools to monitor tumor response in real time,...

Federal Grant Award Summary The National Cancer Institute awarded Ferric Contrast, Inc. a Project Grant totaling $305,253 under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, through July 31, 2026. The award supports the development and preclinical evaluation of iron-based magnetic resonance imaging (MRI) contrast agents as alternatives to gadolinium-based contrast agents (GBCAs). The project involves synthesizing mononuclear and dinuclear iron coordination complexes...

Federal Project Grant Summary O2M Technologies LLC received a $1.164M Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), awarded September 19, 2025, with completion scheduled for August 31, 2027. The grant funds the development of advanced pulse Electron Paramagnetic Resonance Imaging (PEPRI) technology to enable rapid and precise oxygen pressure (pO2) measurements in tissues. Specifically, the project delivers a novel Single...

Federal Project Grant Award Summary Massachusetts General Hospital received a $1,835,840 Project Grant award dated August 1, 2025, under the Research Infrastructure Programs (CFDA 93.351) administered by the National Institutes of Health Office of the Director. The award funds the acquisition and installation of a clinical-grade NVision Polaris C13 Polarizer, an FDA-approved instrument that enables hyperpolarized carbon-13 (C13) magnetic resonance imaging (MRI). This specialized equipment...

Federal Project Grant Award Summary The National Cancer Institute (National Institutes of Health) awarded a $712,375 Project Grant to the University of California, Berkeley under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on April 1, 2026, with a completion date of March 31, 2031. The award funds development of the ADAPT PRO system, a digitally programmable radiofrequency (RF) system designed to enable Magnetic Resonance Imaging (MRI) of any nucleus beyond the standard...

The National Cancer Institute (NCI) awarded a $164,639 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Brown University to develop a novel pipeline for kidney segmentation and registration based on deep learning techniques. The goal is to improve treatment efficacy and reduce recurrence rates for image-guided thermal ablation (IGTA), a minimally invasive cancer treatment. Specifically, the research will focus on detecting and mitigating potentially undetected...

This $215,985 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Leland Stanford Junior University is for a pilot study to sequence exosomal RNA from the blood and urine of 50 patients with renal cell carcinoma. The objective is to identify early biomarkers for therapeutic response to the immune checkpoint inhibitor combination of nivolumab and ipilimumab. The study will analyze changes in the exosomal proteins and RNA,...

This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...